Jones Financial Companies
LCTX icon

Jones Financial Companies’s Lineage Cell Therapeutics LCTX Stock Holding History

Jones Financial Companies’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.71K Buy
4,500
+2,500
+125% +$4.22K ﹤0.01% 3727
2025
Q4 		$3.34K Buy
2,000
+1,100
+122% +$1.9K ﹤0.01% 3662
2025
Q3 		$1.54K Buy
900
+200
+29% +$237 ﹤0.01% 3775
2025
Q2 		$655 Hold
700
– – ﹤0.01% 3751
2025
Q1 		$344 Hold
700
– – ﹤0.01% 3554
2024
Q4 		$351 Buy
+700
New +$514 ﹤0.01% 3268

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $54.7B AUM 26.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jones Financial Companies's LCTX Position: Q1 2026 in Review

Jones Financial Companies increased its Lineage Cell Therapeutics (LCTX) stake by 125% in Q1 2026, buying an estimated $4.22K and bringing the position to 4,500 shares worth $6.71K. The position accounts for ﹤0.01% of the portfolio, ranked #3727.

Jones Financial Companies first reported a position in LCTX in Q4 2024 and has held it in 6 quarters since. 130 funds tracked by Wall St. Rank hold LCTX as of Q1 2026.

  • Jones Financial Companies held 4,500 shares of Lineage Cell Therapeutics worth $6.71K as of Q1 2026.
  • Jones Financial Companies bought 2,500 Lineage Cell Therapeutics shares in Q1 2026, an estimated $4.22K.
  • Lineage Cell Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q1 2026, its #3727 holding.
  • Jones Financial Companies first reported a position in Lineage Cell Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 130 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2026.

Based on Jones Financial Companies's 13F filing for Q1 2026, filed 15 May 2026.